By virtue of a contract, since 2014 Pfizer has held exclusive rights - in the U.S., Europe and the rest of the world - to distribute AstraZeneca's over-the-counter NEXIUM (esomeprazole magnesium), a leading prescription drug currently approved to treat the symptoms of gastro-esophageal reflux disease (GERD). Suppose Pfizer's monopsony and monopoly power from this exclusive deal for NEXIUM is earning unexpectedly huge profits. Is this sufficient justification for AstraZeneca to buy out Pfizer? Explain